Press Room

Press Clipping / Dec 10, 2018

Expansion at Hovione Ireland

Irish Pharma Chem, Industry Buyers Guide, December, 2018

Hovione Loughbeg supplies medium and large-scale manufacturing active pharmaceutical and drug product intermediates that are approved by European, US and Asian health authorities. Over the last four years, the site has continued to successfully transfer new products, acquire new business, achieve multiple regulatory approvals and attract key talent to the site, which now boasts close to 200 team members.

Adding Capacity

In May 2018, Hovione concluded the re-instatement of a second active pharmaceutical ingredient building on the site, adding further significant capacity, technical capability and expansion opportunities. This promising expansion creates career development opportunities for existing and new team members. 
The site now has all three production buildings in operation for the first time in its history. This major investment in the Loughbeg facility will enable further diversity in the product portfolio and brings major additional capacity to the Hovione group, providing enhanced flexibility and agility to both existing and future customers. “We at Hovione Ireland are looking forward to celebrating our 10th year of operation in 2019,” explains Paul Downing, Hovione Ireland General Manager, “which is also the 60th anniversary of the founding of the company in Portugal.”

In It For Life

“Hovione is a pharmaceutical company dedicated to helping pharmaceutical customers bring new and off-patent drugs to market,” Downing explains. “We do well what is difficult, to give our customers what they cannot find elsewhere.”

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025